Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs.
The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical algorithms and bioinformatics to narrow drug choices to those that work with a patient’s genes.
The latest version of the test, GeneSightRx 1.8, adds six new psychotropic medications to the panel of 26 medications covered by the test, according to a statement from AssureRx.
Last year, AssureRx closed an $11 million series B round of funding, led by California-based Claremont Creek Ventures and Sequoia Capital. Other investors include North Coast Angel Fund, Cincinnati Children’s Hospital Medical Center, Mayo Clinic, CincyTech and Allos Ventures.
[Photo from flickr user Harveyben]
Comments
Post a comment
No comments yet.
Post a Comment